What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Raising hemoglobin level with erythropoietin improves cerebral but not muscle tissue oxygenation in patients with sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

Erythropoietin treatment raises hemoglobin and increases cerebral oxygenation in sickle cell disease, indicating a potential therapeutic avenue.

Erythropoietin treatment effectively raised hemoglobin levels in patients suffering from sickle cell disease, resulting in enhanced cerebral tissue oxygenation.
A total of 16 patients completed EPO treatment, with significant increases in cerebral oxygen saturation observed at 12 weeks, while muscle oxygen levels remained constant.
Continuous-wave near-infrared spectroscopy was employed to track tissue oxygen saturation changes throughout the intervention period over 24 weeks.
Findings emphasize the need to understand the differential impact of treatments on cerebral and peripheral microvascular hemodynamics.

Tukakira et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Erythropoietin treatment raises hemoglobin and increases cerebral oxygenation in sickle cell disease, indicating a potential therapeutic avenue.